Mars Pharma Profile
Key Indicators
- Authorised Capital ₹ 4.50 M
as on 02-01-2025
- Paid Up Capital ₹ 4.10 M
as on 02-01-2025
- Company Age 11 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.00 Cr
as on 02-01-2025
- Revenue -45.18%
(FY 2023)
- Profit -83.37%
(FY 2023)
- Ebitda -88.63%
(FY 2023)
- Net Worth 880.87%
(FY 2023)
- Total Assets -3.52%
(FY 2023)
About Mars Pharma
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.50 M and a paid-up capital of Rs 4.10 M.
The company has closed loans amounting to ₹1.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Apparao Pullela and Rajasekhar Pullela serve as directors at the Company.
- CIN/LLPIN
U24290TG2013PTC089097
- Company No.
089097
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jul 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Mars Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajasekhar Pullela  | Managing Director | 23-Jul-2013 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Apparao Pullela | Director | 08-Sep-2021 | Current |
Financial Performance of Mars Pharma.
Mars Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 45.18% decrease. The company also saw a substantial fall in profitability, with a 83.37% decrease in profit. The company's net worth Soared by an impressive increase of 880.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mars Pharma?
Unlock access to Mars Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Mars Therapeutics Private LimitedActive 31 years 9 monthsApparao Pullela and Rajasekhar Pullela are mutual person
Aarvi Pharmatech LlpActive 2 years 5 monthsApparao Pullela and Rajasekhar Pullela are mutual person
Charges (Loans)
₹0
₹10.00 M
Charges Breakdown by Lending Institutions
- Others : 1.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Jun 2022 | Others | ₹1.00 Cr | Satisfied |
How Many Employees Work at Mars Pharma?
Mars Pharma has a workforce of 73 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mars Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mars Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
